Ramadan Afaf A, Elbakry Asmaa M, Esmaeil Asmaa H, Khaleel Sahar A
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.
2Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.
J Pharm Investig. 2018;48(6):673-683. doi: 10.1007/s40005-017-0365-1. Epub 2017 Nov 14.
The objective of the present study was to develop rectal mucoadhesive hydrogels loaded with Tolmetin Sodium, a non-steroidal anti-inflammatory drug, for prolonged duration of action and increased bioavailability. Fourteen formulae were prepared with different types and concentrations of polymers as hydroxypropylmethyl cellulose, hydroxylethyl cellulose, carboxymethyl cellulose and sodium alginate. Each formulation contain Tolmetin Sodium equivalent to 5% w/w active drug. The effect of the employed gel bases on pH, gel strength, mucoadhesion, viscosity and the in vitro release profile of drug was examined. In addition, hydrogel formulations were subjected to rheological and stability studies. The physicochemical characterization revealed that all hydrogels had a suitable pH (6.64-7.75) and gel strength (15.5-65.29 s) for rectal application. The in-vitro drug release from the formulations showed a controlled drug release pattern, reaching 72-92.6% after 8 h. The kinetic analysis of the release data revealed that the drug release from all tested hydrogel bases obeyed the diffusion mechanism. The degradation of Tolmetin Sodium from its rectal hydrogel formulations was found to be a zero-order reaction. All formulations except sodium alginate hydrogel were quite stable. Considering the in-vitro release, rheological properties and shelf life, (CMC; 2%w/w) hydrogel formula was the best among the studied formulations. Therefore, further histopathological and bioavailability studies were carried out to detect different pharmacokinetic parameters of the established formulations compared with commercially available capsules. Formula containing 2% CMC showed relative bioavailability 357.93%. Finally, good correlation was observed between in-vitro and in-vivo profile.
本研究的目的是开发一种载有非甾体抗炎药托美丁钠的直肠黏膜黏附水凝胶,以延长作用时间并提高生物利用度。使用不同类型和浓度的聚合物(如羟丙基甲基纤维素、羟乙基纤维素、羧甲基纤维素和海藻酸钠)制备了14种配方。每种配方均含有相当于5%w/w活性药物的托美丁钠。考察了所用凝胶基质对pH值、凝胶强度、黏膜黏附性、粘度以及药物体外释放曲线的影响。此外,对水凝胶制剂进行了流变学和稳定性研究。物理化学表征表明,所有水凝胶的pH值(6.64 - 7.75)和凝胶强度(15.5 - 65.29秒)均适合直肠给药。制剂的体外药物释放呈现出控释模式,8小时后释放率达到72 - 92.6%。释放数据的动力学分析表明,所有测试水凝胶基质的药物释放均符合扩散机制。发现托美丁钠从其直肠水凝胶制剂中的降解为零级反应。除海藻酸钠水凝胶外,所有制剂都相当稳定。考虑到体外释放、流变学性质和保质期,(羧甲基纤维素;2%w/w)水凝胶配方是所研究配方中最佳的。因此,进行了进一步的组织病理学和生物利用度研究,以检测所制备配方与市售胶囊相比的不同药代动力学参数。含2%羧甲基纤维素的配方显示相对生物利用度为357.93%。最后,观察到体外和体内曲线之间具有良好的相关性。